Perrigo Company plc Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net
Perrigo Company plc (PRGO) reported Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net of $1.30 million for the 12-month period ending 2017-12-31, per its 10-K filed 2020-02-27.
Discontinued › Income Statement › Other Income
us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet · last filed 2020-02-27
- Perrigo Company plc derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for the quarter ending 2017-12-31 was $100.00K.
- Perrigo Company plc derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for the quarter ending 2017-09-30 was $300.00K.
- Perrigo Company plc derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for the quarter ending 2017-07-01 was $100.00K, a 75.00% decline year-over-year.
- Perrigo Company plc derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for the quarter ending 2017-04-01 was $900.00K.
- Perrigo Company plc derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for fiscal 2017 was $1.30M.
- Perrigo Company plc derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for fiscal 2016 was -$300.00K.
- Perrigo Company plc derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for fiscal 2015 was -$1.00M.
- Perrigo Company plc derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for fiscal 2014 was -$2.90M, a 1550.00% decline from fiscal 2013.
| Period end | Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net 3 month | Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net 6 month | Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net 9 month | Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net 12 month | Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net 12 month as first filed |
|---|---|---|---|---|---|
| 2017-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $400.00K derived: sum of 2 quarters · filed 2020-02-27 | $500.00K derived: sum of 3 quarters · filed 2020-02-27 | $1.30M 10-K · filed 2020-02-27 | |
| 2017-09-30 | $300.00K 10-Q · filed 2018-11-08 | $400.00K derived: sum of 2 quarters · filed 2018-11-08 | $1.20M 10-Q · filed 2018-11-08 | $400.00K derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-07-01 | $100.00K 10-Q · filed 2017-08-10 | $1.00M 10-Q · filed 2017-08-10 | $100.00K derived: sum of 3 quarters · filed 2019-02-27 | $100.00K derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-04-01 | $900.00K 10-Q · filed 2017-05-30 | $0.00 derived: sum of 2 quarters · filed 2019-02-27 | $0.00 derived: sum of 3 quarters · filed 2019-02-27 | $400.00K derived: sum of 4 quarters · filed 2019-02-27 | |
| 2016-12-31 | -$900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | -$900.00K derived: sum of 2 quarters · filed 2019-02-27 | -$500.00K derived: sum of 3 quarters · filed 2019-02-27 | -$300.00K 10-K · filed 2019-02-27 | $300.00K 10-K · filed 2017-05-22 |
| 2016-10-01 | $0.00 10-Q · filed 2017-11-09 | $400.00K derived: sum of 2 quarters · filed 2017-11-09 | $600.00K 10-Q · filed 2017-11-09 | $400.00K derived: sum of 4 quarters · filed 2018-03-01 | |
| 2016-07-02 | $400.00K 10-Q · filed 2017-08-10 | $600.00K 10-Q · filed 2017-08-10 | $400.00K derived: sum of 3 quarters · filed 2018-03-01 | $400.00K derived: sum of 4 quarters · filed 2018-03-01 | |
| 2016-04-02 | -$100.00K 10-Q · filed 2017-05-30 | $0.00 derived: sum of 2 quarters · filed 2018-03-01 | $0.00 derived: sum of 3 quarters · filed 2018-03-01 | $100.00K derived: sum of 4 quarters · filed 2018-03-01 | |
| 2015-12-31 | $100.00K derived: 10-K 6 month − 10-Q/A 3 month · filed 2018-03-01 | $100.00K 10-K · filed 2018-03-01 | $200.00K derived: sum of 3 quarters · filed 2018-03-01 | $100.00K derived: sum of 4 quarters · filed 2018-03-01 | |
| 2015-09-26 | $0.00 10-Q/A · filed 2017-05-23 | $100.00K derived: sum of 2 quarters · filed 2017-05-23 | -$200.00K 10-Q/A · filed 2017-05-23 | -$800.00K derived: sum of 4 quarters · filed 2017-05-23 | |
| 2015-06-27 | $100.00K 10-Q/A · filed 2017-05-22 | -$200.00K 10-Q/A · filed 2017-05-22 | -$800.00K derived: sum of 3 quarters · filed 2017-05-22 | -$1.00M 10-K · filed 2018-03-01 | |
| 2015-03-28 | -$100.00K 10-Q/A · filed 2017-05-22 | -$900.00K derived: sum of 2 quarters · filed 2017-05-22 | -$1.10M 10-Q · filed 2015-04-29 | -$500.00K derived: sum of 4 quarters · filed 2017-05-22 | |
| 2014-12-27 | -$800.00K 10-Q · filed 2015-02-05 | -$800.00K 10-Q · filed 2015-02-05 | -$400.00K derived: sum of 3 quarters · filed 2017-05-22 | -$400.00K derived: sum of 4 quarters · filed 2017-05-22 | |
| 2014-09-27 | $0.00 8-K · filed 2014-11-20 | $400.00K derived: sum of 2 quarters · filed 2017-05-22 | $400.00K derived: sum of 3 quarters · filed 2017-05-22 | -$2.20M derived: sum of 4 quarters · filed 2017-05-22 | |
| 2014-06-28 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-05-22 | $400.00K derived: sum of 2 quarters · filed 2017-05-22 | -$2.20M derived: sum of 3 quarters · filed 2017-05-22 | -$2.90M 10-K · filed 2017-05-22 | $2.90M 10-K · filed 2014-08-14 |
| 2014-03-29 | $0.00 10-Q · filed 2015-04-29 | -$2.60M derived: sum of 2 quarters · filed 2015-04-29 | -$3.30M 10-Q · filed 2015-04-29 | ||
| 2013-12-28 | -$2.60M 10-Q · filed 2015-02-05 | -$3.30M 10-Q · filed 2015-02-05 | |||
| 2013-09-28 | -$400.00K 8-K · filed 2014-11-20 | ||||
| 2013-06-29 | $200.00K 10-KT · filed 2016-02-25 | -$200.00K 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |